Association of inflammatory markers with colorectal cancer incidence in the Atherosclerosis Risk in Communities (ARIC) study

Anna E Prizment[1], **Kristin E Anderson**[1,2], **Kala Visvanathan**[3], and **Aaron R Folsom**[1,2]

[1]Division of Epidemiology and Community Health, School of Public Health, University of Minnesota, Minneapolis, MN

[2]University of Minnesota Masonic Cancer Center, University of Minnesota, Minneapolis, MN

[3]Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD

Abstract

Background—Chronic inflammation has been implicated in the etiology of colorectal cancer (CRC), but epidemiological findings on the association between circulating inflammatory markers and CRC risk are inconsistent. We hypothesized that increased concentrations of systemic inflammatory markers – white blood cell count (WBC), fibrinogen, von Willebrand factor (VWF), factor VIII (FVIII), and C-reactive protein (CRP) – and decreased albumin concentration would be associated with increased CRC risk in the ARIC prospective cohort.

Methods—WBC, fibrinogen, VWF, FVIII, and albumin, measured in 1987–89 in 13,414 men and women, were transformed to *Z* scores and summed up to construct a blood "inflammation Z-score". Albumin was included with a negative sign, since its concentration decreases with greater inflammation. A total of 308 incident CRC cases were identified through 2006 in initially cancer-free participants. CRP was measured in 1996–98 in 9,836 cancer-free people who developed 166 CRCs through 2006. Proportional hazard models were used to estimate the hazard ratios (HR) and (95% confidence interval, CI) of CRC in relation to each individual marker and the inflammation Z-score.

Results—After multivariate adjustment, for the highest versus lowest quartile, there was a statistically significant positive association of CRC risk with fibrinogen: HR =1.50 (95%CI, 1.05;2.15) (p-trend across quartiles was 0.03), inflammation Z-score: HR=1.65 (95%CI, 1.15;2.35) (p-trend=0.01), and CRP: HR=1.97 (95%CI, 1.13;3.43) (p-trend=0.02).

Conclusions—These findings indicate that greater levels of fibrinogen, CRP, and blood inflammation Z-score are associated with increased CRC risk.

Impact—The study provides further evidence that pre-cancer inflammation may contribute to CRC etiology.

Keywords

acute-phase reactants; C-reactive protein; colorectal cancer; inflammation; prospective study

Correspondence to Anna E. Prizment, PhD, MPH, Division of Epidemiology and Community Health, 1300 2nd Street South, Suite 300, University of Minnesota, Minneapolis, MN 55455, USA (phone +1-612-626-0250, fax: +1-612-624-0315. prizm001@umn.edu).

INTRODUCTION

Chronic inflammation has been previously linked to the etiology of cancer (1, 2). The evidence is strongest for colorectal cancer (CRC). It has been shown that colonic inflammatory bowel disease, especially ulcerative colitis, increases CRC risk (3, 4), whereas nonsteroidal anti-inflammatory drugs (NSAIDs) reduce CRC risk (3, 5). Moreover, several epidemiological studies observed positive associations between circulating C-reactive protein (CRP) – a non-specific marker of systemic inflammation – and CRC risk (6–9). The odds ratio of CRC was increased by 60–190% for the highest versus lowest CRP quartile in three studies (6, 7, 9), and by 40% per 1 unit of log-transformed CRP in the fourth study (8). However, data from other studies on CRP and CRC risk are inconsistent, and few studies have examined inflammatory biomarkers other than CRP in relation to incident CRC (10–12). More observational data on a wide range of inflammatory biomarkers, particularly from large prospective cohorts, are needed to further examine the role of inflammation in the etiology of CRC .

Our objective was to investigate associations of six circulating markers of systemic inflammatory response, including C-reactive protein (CRP), white blood cell (WBC) count, fibrinogen, von Willebrand factor (VWF), Factor VIII (FVIII), and albumin with CRC risk in the ARIC prospective cohort. These acute phase reactants change their concentrations in response to acute inflammation by at least 25%: the level of positive acute phase reactants such as WBC, fibrinogen, VWF, FVIII, and CRP increase, whereas the level of albumin – a negative reactant – decreases (13). The acute phase reactants are components of the innate immune system, mainly produced by hepatocytes under stimulation with inflammatory cytokines, such as interleukins: IL-6, IL1-β, IL-8, tumor necrosis factor-α, interferon-γ, and transforming growth factor-β (13).

When excessive inflammation persists for a long time, it leads to chronic inflammation which is associated with a modest increase in the levels of acute-phase reactants. It is characterized by infiltration with macrophages, lymphocytes, and plasma cells; the secretion of cyclo-oxygenase-2 (COX-2)and prostaglandinsin macrophages and epithelial cells; and tissue destruction due to continuous production of reactive oxygen and nitrogen species (2). Taken together, these processes may lead to cell changes and development of cancer, particularly of colorectal cancer (14, 15). Colon may be especially prone to carcinogenesis via inflammation, because of rapidly-dividing cells and the presence of microbial flora causing permanent low-grade inflammation of colon mucosa (4, 15).

Our hypothesis was that increased concentrations of positive acute phase reactants, CRP, WBC, fibrinogen, VWF, and FVIII, and decreased concentration of a negative-phase reactant, albumin, measured before CRC diagnosis, are associated with increased future incidence of CRC. We examined the associations of CRC risk in relation to each individual marker and to a combined inflammation Z-score created from biomarkers at baseline. To the best of our knowledge, our study is the first to examine an inflammation score in relation to CRC incidence.

MATERIALS AND METHODS

Study design and population

ARIC is a multicenter population-based prospective cohort study of atherosclerosis. Details of the ARIC cohort have been published elsewhere (16). In brief, in 1987–89, 15,792 volunteers aged 45–69 were recruited from four communities: suburban Minneapolis, MN, Forsyth County, NC, Jackson, MS, and Washington County, MD. The cohort underwent re-

examination visits every 3 years, with 93% response for Visit 2 (1990–92), 86% response for Visit 3 (1993 – 95), and 81% response for Visit 4 (1996–98).

Local institutional review boards approved the ARIC protocol and all participants provided an informed consent, which included consent for follow-up for disease occurrence.

Data collection

Home interviews and medical examinations were conducted at each visit. At baseline (Visit 1), participants were asked to report their demographic characteristics, education, and lifestyle behaviors including alcohol drinking status, smoking status, number of cigarettes per day, and duration of smoking (pack years were computed). Trained personnel collected blood (serum and plasma) samples and performed anthropometric measures which were shown to be reliable (17). Data collection and quality-control methods have been described in detail (18). Usual food intake during the previous year was collected by using a modified version of the Willett 61-item semiquantitative food frequency questionnaire (19). Regular physical activity was assessed by the Baecke questionnaire and semi-continuous sport index was calculated (20). Prevalent diabetes mellitus was defined as a fasting glucose ≥126 mg/dl, non-fasting plasma glucose >200 mg/dL, a self-reported physician diagnosis of diabetes, or current treatment for diabetes. Participants were queried about their history of cancer and about aspirin use during the last two weeks before the examination. Dosage and frequency of aspirin use was not ascertained. Participants were asked to bring to the clinic all medications taken during the 2 weeks prior to the examination; thus data about oral contraceptives and hormone replacement therapy (HRT) were collected.

For the analysis of CRP, most of the variables were obtained from Visit 4, as blood samples for CRP measurements were collected during that visit. Additional data about cancer risk factors were collected from the telephone interview in 1994–96 (response 90%), which included history of non-aspirin NSAIDs use at Visit 1 and Visit 4, history of cancer in first-degree relatives, lifetime history of sigmoidoscopy/colonoscopy, testing for blood in the stool, history of polyps, and history of non-cancerous tumors in the colon or rectum.

Biological markers

At each visit, ARIC technicians used standard protocols to draw fasting blood, centrifuge samples and freeze plasma and blood samples at −70C until analysis (21). With the exception of WBC count, which was measured in local hospitals, all biomarkers at baseline – fibrinogen (mg/dL), VWF (% of standard), FVIII activity (% of standard), and albumin (g/dL) – were analyzed in ARIC research laboratories using standardized protocols (described in detail in (22)). The reliability coefficients, based on repeated testing of individuals over 1–2 weeks, were 0.72 for fibrinogen, 0.86 for FVIII activity, 0.68 for VWF, 0.69 for albumin, and 0.96–1.00 for WBC (23).

High-sensitivity (hs) CRP (mg/L) was measured in 2008 on plasma frozen at −70°C from Visit 4 (1996–98) by the immunoturbidimetric assay using the Siemens (Dade Behring) BNII analyzer (Dade Behring, Deerfield, Il, USA). Approximately four percent of the samples were split and measured as blinded replicates on different dates to assess repeatability. The reliability coefficient for blinded quality control replicates of CRP was 0.99 (421 blinded replicates) (24).

Ascertainment of incident colorectal cancer cases

Incident cancers were ascertained in 1987–2006 by linkage to cancer registries and supplemented by hospital records. Minneapolis, Forsyth County, and Washington County were covered by state or county cancer registries and reported high completeness of cancer

data (25, 26). After 1995, a state registry also covered Jackson but it was not always complete. ARIC hospital surveillance was used to identify additional cancer cases. For participants who had hospital ICD (International Classification of Diseases) codes for cancer that were not in cancer registries, records of hospitalized events were obtained and reviewed. Primary site, date of cancer diagnosis, and source of diagnostic information (e.g., a pathology report) were recorded. Data on stage were not uniformly collected.

Statistical analysis

We created an inflammation Z-score from five inflammatory biomarkers measured at baseline: fibrinogen, VWF, factor VIII, albumin, and WBC. Since WBC was not normally distributed, log transformed WBC was used. Each biomarker was rescaled to have a mean of zero and a standard deviation of one, and normalized z-scores were obtained for each biomarker ($z = (x - \mu)/\sigma$, where x is the biomarker value, μ is the mean, and σ is the standard deviation). The z-scores from all biomarkers were summed up to create a combined Z-score. Albumin was included with a negative sign because its concentration decreases in response to inflammation.

The only biomarker measured in samples from Visit 4 was CRP. We examined covariates across quartiles of all the five biomarkers and the inflammation score at baseline and CRP at Visit 4 using general linear models or chi-square tests. In addition, we measured correlations between biomarkers at baseline using Pearson correlations.

For analyses of CRC in relation to the inflammatory Z-score and biomarkers measured at baseline, person-years at risk were calculated from the baseline examination date to the date of CRC diagnosis, death, loss to follow-up, or December 31, 2006, whichever occurred first. For the analysis of CRP, person-years were calculated from Visit 4.

Poisson regression was used to calculate incidence rates of CRC, adjusted for age, sex, race, and center, and 95% confidence intervals (CI). The proportional hazards model was used to estimate the hazard ratios of incident CRC and 95% CI for quartiles of each biomarker and the inflammation score. Tests for trend across the quartiles of each biomarker were computed by treating the quartiles as continuous ordinal variables. Proportional hazards assumptions were tested by including an interaction term between each inflammatory marker and follow-up time in a Cox regression model. There was no evidence that these assumptions were violated for any marker. For each inflammatory marker, there were two models: 1) adjusted for age, sex, race, and center and 2) multivariate-adjusted, which included covariates associated with any inflammatory marker under study and with CRC. The multivariate model for biomarkers at baseline included age (continuous), race (Caucasian, African American), center, education level (less than high school, high school, more than high school), BMI (less than 25, 25–29.9, and $\geq$30 kg/m^2), aspirin use (yes/no), smoking status (never, former, current), pack-years of smoking (continuous), gender-HRT (men, women never taking HRT, and women who were former or current HRT users), and diabetes (yes/no) measured at baseline. Additional variables that were tested for confounding but were not included in the final models were alcohol intake, sport index, consumption of red meat, dietary fiber, calcium, history of non-aspirin NSAIDs use, and family history of CRC. The multivariate model for the analysis of CRP included baseline variables: race, center, and education level, and variables collected at Visit 4: age, gender-HRT, BMI, smoking status, aspirin and diabetes. For this analysis, variables measured in 1994–96 – history of non-aspirin NSAIDs use, history of sigmoidoscopy/colonoscopy, test for blood in the stool, history of polyps, and history of non-cancerous tumors in the colon or rectum – were also tested as potential confounders. Since none of these variables, nor dietary factors materially changed the association between CRP and CRC risk, they were not included in the final multivariate model. Because information on acute inflammatory

diseases was not collected, in order to exclude acute inflammatory response, we repeated the main analysis after excluding people with CRP values > 10 mg/L (N=767). Additionally, participants were categorized into three CRP groups according to the cutoff points proposed in clinical guidelines for cardiovascular disease: less than 1, 1 to 3, and greater than 3 mg/L (27).

We also ran exploratory analyses separately for colon and rectal cancer for each biomarker associated with CRC risk. We tested statistically if observed associations varied across race, sex, smoking status, BMI, or aspirin use by introduction of cross-product interaction terms into a multivariate model for each biomarker associated with CRC. Since the p-values for all interaction terms were greater than 0.2, we assumed that there were no interactions. Of note, power was limited, especially for the analysis of CRP. Finally, we repeated analyses by excluding CRC cases that occurred within 1, 2, and 5 years of follow-up, in order to exclude the potential influence of subclinical CRC on the levels of biomarkers.

All analyses were conducted using SAS (SAS Institute, Inc., Cary, NC) (version 9.2). Participants, who had prevalent cancer at the start of follow-up or did not give consent to participate in cancer studies, or had missing information about the biomarkers under study, were excluded from the analyses.

Results

At baseline, the mean age of the cohort was 53.9 years, 26% were African American (74% Caucasian) and 54% were women. During 230,509 person-years of follow-up (mean follow-up was 17.2 years) from 1987 through 2006, there were 308 incident CRC cases (232 colon and 78 rectal) in 13,414 people at risk.

CRP was measured at Visit 4 in 1996–98. The mean age of the cohort at Visit 4 was 62.6 years, 23% were African American and 54% were women. There were 166 incident cases of CRC (133 colon and 35 rectal) in 9,836 people at risk followed from Visit 4 through 2006 (over 87,585 person-years of follow-up with mean of 8.9 years).

Incidence rates of CRC adjusted for age, sex, race, and study center in 1987–2006 are presented in Table 1. Rates of CRC increased with age, BMI, and with lower education level. They were higher in men than in women and in African Americans than in Caucasians. CRC rates were also higher among current smokers, alcohol users, and slightly lower among users of aspirin or HRT compared to never users.

Baseline inflammatory markers were correlated: FVIII with VWF (Pearson r=0.71); fibrinogen with FVIII (r=0.25) or VWF (r=0.28); albumin with FVIII (r=−0.19) or VWF (r=−0.16) or fibrinogen (r=−0.21); and WBC with fibrinogen (r=0.27). Although CRP was not measured for all participants at baseline, it was measured in a cohort random sample and was shown to be positively associated with fibrinogen (r=0.53), WBC count (r=0.23), VWF (r=0.29), and FVIII (r=0.31) (unpublished data).

Table 2 shows that inflammation Z-score increased with a greater age, BMI, and percentages of women, African Americans, current smokers, aspirin users, and diabetics. The Z-score was inversely associated with sport index, current alcohol and HRT use, and education beyond high school. Age, education, BMI, diabetes, and sport index were distributed in a similar way across all biomarkers at baseline (inverse directions for albumin). However, several covariates were distributed differently across the biomarkers: as WBC count increased, the percentage of alcohol users and Caucasians increased and percentage of women decreased (Supplemental Table 1). FVIII and VWF were inversely associated with smoking, and albumin was inversely associated with HRT use (Supplemental Tables 2–3).

The findings for individual markers are in agreement with findings from other studies (10, 11, 28).

Similar to the patterns for Z-score, the percentage of African Americans and females was higher among those with higher CRP (Table 3). CRP was positively associated with BMI, smoking, and diabetes, and inversely associated with sport index and alcohol intake. The percentage of HRT users increased with increasing CRP. These relations were similar to those observed in other studies on CRP (7, 9, 29, 30),

Hazard ratios of CRC were slightly increased for the highest versus lowest quartile of fibrinogen, VWF, FVIII, and WBC (Table 4). However, only the association between fibrinogen and CRC incidence was statistically significant: multivariate-adjusted HR=1.50 (95%CI, 1.05; 2.15) for the highest versus lowest quartile (p-trend=0.03). There was also a positive association of the inflammation Z-score with CRC risk: HR=1.65 (95%CI, 1.15; 2.35) for the highest versus lowest quartile (p-trend=0.01) (Table 4). The associations with fibrinogen and Z-score were stronger for colon cancer, and no associations with rectal cancer were observed (Table 5). To examine if the association between inflammation Z-score and CRC risk was driven by fibrinogen, a new inflammation score was created which summed up Z-scores for logarithm of WBC count, VWF, FVIII and subtracted the Z-score for albumin (fibrinogen was not included). The multivariate hazard ratio of CRC was also increased for the new Z-score: 1.52 (95%CI, 1.08; 2.15) for the highest versus lowest quartile (p-trend=0.04).

After excluding CRC cases within 1, 2, or 5 years of follow-up, positive associations of fibrinogen and the inflammation Z-score with CRC incidence remained statistically significant. For instance, after excluding CRCs within 5 years of follow-up, multivariate-adjusted HRs for the highest versus lowest quartile were 1.67 (95%CI, 1.13; 2.45) (p-trend=0.01) for the Z-score and 1.65 (95%CI, 1.11; 2.46) (p-trend=0.01) for fibrinogen.

CRP was positively associated with CRC risk: in the multivariate-adjusted model: HR=1.97 (95%CI, 1.13; 3.43) for the highest versus lowest quartile (p-trend=0.02) (Table 6). The multivariate-adjusted HR of colon cancer incidence was slightly higher: 2.06 (95%CI, 1.12; 3.79) for the highest versus lowest CRP quartile (p-trend=0.02). No association of CRP with rectal cancer was observed, but the number of rectal cancers was low (N=35) (Table 6).

When CRP was presented as standard categories, the statistically significant association remained: compared to CRP<1 mg/L, multivariate-adjusted HRs were 1.43 (95%CI, 0.86; 2.38) for 1–3 mg/L and 1.76 (95%CI, 1.05; 2.93) for CRP>3 mg/L (p-trend=0.03).

Exclusion of people with CRP values > 10 mg/L (N=767), i.e., those with potential acute inflammatory responses, yielded similar results: multivariate-adjusted HR=1.99 (95%CI, 1.10; 3.60) for the highest versus lowest CRP quartile (p=0.02). After excluding cancer cases within 1, 2, or 5 years after the Visit 4 examination, the HRs for the highest versus lowest CRP quartile were 2.04 (95%CI, 1.13; 3.70) (p-trend=0.02), 1.77 (95%CI, 1.01; 3.09) (p-trend=0.05), and 2.12 (95%CI, 0.88; 5.11) (p-trend=0.33), respectively.

DISCUSSION

This prospective study found a 97% increased hazard ratio of incident CRC for the highest versus lowest CRP quartile (p-trend=0.02). There were also statistically significant positive associations of CRC in relation to fibrinogen level (50% greater for the highest than for the lowest quartile, p-trend=0.03), and the inflammation Z-score (65% greater for the highest than for the lowest quartile, p-trend=0.01). These associations were limited to colon cancer, with no associations observed for rectal cancer. The inflammation Z-score without

fibrinogen was also positively associated with CRC risk (51% greater for the highest than for the lowest quartile, p-trend=0.04), although no association was detected for any individual marker. Thus, a combination of several inflammatory markers may be a better indicator of inflammatory processes associated with CRC risk than any of these markers individually.

Recently, several studies showed that an increased inflammation score including albumin and CRP (Glasgow prognostic score) predicts poorer survival of CRC patients (31, 32). To our knowledge, no other study has examined a combination of inflammatory markers in relation to CRC risk. The fact, that we found positive associations of CRP, fibrinogen and inflammation Z-scores with CRC risk, supports the hypothesis that chronic inflammation, reflected by acute-phase reactants measured before cancer diagnosis, may play a role in CRC development. Similar results were observed after excluding CRC cases within 1, 2 and 5 years of follow-up, i.e. excluding the potential influence of preclinical CRC on the concentration of the inflammatory markers.

Overall, previous epidemiological data on CRP and CRC risk are contradictory. Our results for CRP are in agreement with the findings of four nested case-control studies (6–9). Three among them reported OR=1.6–2.9 of CRC for the highest versus lowest CRP quartile (6, 7, 9), and the remaining study reported OR=1.44 (95%CI, 1.03; 2.02) per 1 unit of log CRP (8). In our cohort, the HR of CRC per 1 unit of log-transformed CRP was 1.26 (95%CI, 1.06; 1.49). Similar to our study, Erlinger et al [2004] observed a stronger association of CRP with colon cancer and no association with rectal cancer (6). A prospective study from the Netherlands reported no association of CRP with total CRC risk, but a positive association for non-sigmoid colon cancer: RR= 1.48 (95%CI, 1.14; 1.94) per 1 standard deviation (SD) of CRP (33). In contrast, three studies – the Japan Collaborative Cohort Study, the European Prospective Investigation into Cancer and Nutrition in Greece, and the Women's Health Study did not find statistically significant associations between CRP concentration and incident CRC (29, 34, 35). In the Women's Health Study, there was an indication of an inverse CRP – CRC association (29). The Women's Health Study could be different from other studies in a number of ways because it included only female health professionals who participated in a clinical trial of low aspirin and vitamin E and used HRT more frequently than populations in other studies. Two meta-analyses of prospective studies of CRP and risk of CRC were published in 2008 (36, 37). Both reported a slightly increased risk of CRC in relation to CRP: HR=1.09 (95% CI, 0.98; 1.21) and 1.12 (95% CI, 1.01; 1.25) per one unit in log-transformed high-sensitivity CRP in Heikkila et al [2009] (36) and Tsilidis et al [2008] (37), respectively. The analysis by Tsilidis et al [2008] reported slightly increased risk of colon cancer and no risk of rectal cancer in relation to greater CRP (37), which is in line with our results. Heikkila et al [2008] indicated that the "results of some studies were inconsistent", with relatively high heterogeneity among the effect estimates as reflected by $I^2 = 50.2$. They concluded that there was a need for large prospective studies specifically designed to investigate the relation between CRP concentration and CRC risk (36). Recently, a Danish prospective cohort reported an increased multivariate-adjusted hazard ratio of incident CRC for the highest versus lowest quintile of CRP: 1.7 (95% CI, 0.8; 3.2) (p-trend = 0.33), but the number of CRC cases was small (N=93) (30). There is no clear explanation for the different findings among studies but some reasons may include different study populations and insufficient adjustment for confounding factors such as obesity, smoking, use of NSAIDs, or diabetes.

The epidemiological evidence for other acute-phase reactants and CRC risk is sparse and inconsistent. Two studies reported positive statistically significant associations between WBC and incident CRC: HRs were 1.15–1.24 for the upper versus lowest WBC quartile, which are slightly higher than HR=1.13 observed in our cohort (10, 11). Two other studies

had contradictory findings on serum albumin concentrations in relation to CRC incidence: Knekt et al [2000] observed positive associations between albumin concentrations and risk of distal colon cancer (38), whereas Ko et al [1994] reported an inverse relation between albumin and colon cancer risk (p-trend=0.02) (12). To our knowledge, no epidemiological studies examined associations of incident CRC in relation to fibrinogen, VWF, or FVIII. A large meta-analysis of prospective studies reported a positive association of fibrinogen with mortality from CRC: HR=1.71 (95%CI, 1.30; 2.25) per 1 g/L increment in fibrinogen (28).

Several lines of evidence support a role of colonic inflammation in colorectal carcinogenesis. Laboratory animal studies indicate that inflammation promotes the conversion of colonic adenoma cells to adenocarcinoma cells (39). In humans, reactive oxygen species and nuclear factor kappa B, which activates the cytokine cascade and other pro-inflammatory mediators, have been shown to be expressed in colon tissues (2, 14). Genetic polymorphisms of COX-2 (2, 10) and several genetic polymorphisms in inflammatory cytokine genes (40–42) have been associated with an increased risk of colorectal adenomas or CRC. An increased CRC risk in patients with inflammatory bowel disease (the risk markedly increases with the extent and duration of disease) (3, 4) and protective effects of long-term use of NSAIDs for incident CRC in observational studies and randomized trials (3, 5) strongly support a link between inflammation and CRC.

The mechanisms explaining the biological association between inflammatory markers and CRC development are unclear but acute phase reactants measured before CRC diagnosis may play several roles in the process. First, any association between acute-phase reactants and CRC incidence may be causal, i.e. acute-phase reactants themselves may increase the CRC risk most likely by perpetuating inflammation. For instance, in mice, fibrinogen (its $\alpha_M\beta_2$ binding motif)has been shown to cause local inflammatory processes (secretion of interleukin-6) and epithelial alterations that result in epithelial hyperplasia and secondary transformation events leading to colitis-associated colon cancer (43). Further, WBCs produce oxygen metabolites causing DNA damage in mammalian cells (44), and CRP activates endothelial cells, monocytes, and smooth muscle cells and induces the NF-κB inflammatory pathway, which may lead to CRC (45, 46).

Alternatively, an association between acute-phase reactants and CRC incidence may be non-causal with acute-phase reactants simply being indicators of chronic inflammation. The inflammation may start directly in the colon or may be a consequence of systemic inflammation: circulating proinflammatory mediators increase gut permeability and exposure to luminal antigens, which induces a local immune response and mucosal inflammation in the colon (47). Although the present study cannot determine whether acute phase reactants are actively involved in the carcinogenesis or are merely bystanders, the positive associations of these biomarkers with subsequent CRC risk may help predict cancer risk in the future.

Our study has several important strengths: prospective design, large sample size, long follow-up with a high participation rate, detailed information about potential confounding variables, and accurate measurement of several acute-phase reactants. The ARIC study used standardized validated protocols in four centers. Availability of data on five acute-phase reactants – non-specific markers of systemic inflammation at baseline – allowed us not only to study the association for each individual marker but also to examine their combined association with CRC incidence.

However, there are important limitations. ARIC was not designed for cancer research. Information about some cancer risk factors and cancer screening became available only 7–8 years after baseline. Although we adjusted for many confounders, as in any observational

study, we cannot exclude residual confounding, for instance by dietary factors, which are difficult to measure and adjust for (36). Further, there was likely incomplete ascertainment of cancer cases in the Mississippi cohort. However, we do not have a reason to presume that these missing cases were associated with inflammatory markers. In addition, data on cancer stage or CRC subsites were not uniformly available from the registries.

Another concern is that our markers reflect not only chronic but also acute phase response. To address this issue, we excluded participants with CRP>10 mg/L (mild and acute inflammation) (48) and obtained similar associations of CRP with CRC risk. Further, misclassification could arise from using single measurements of inflammatory markers, which most likely results in underestimation of hazard ratios, although the reliability coefficients based on repeated testing of individuals over 1–2 weeks were ≥0.69 for baseline markers in ARIC (23). Most studies reported reliability coefficients for CRP of at least 0.6 (8, 49). Another limitation is that we do not know whether the measured circulatory markers correlate with relevant inflammatory markers in normal colon tissue. Moreover, it was impossible to distinguish whether elevated levels of those biomarkers are associated with CRC risk only through inflammation or because of some other functions such as procoagulant properties of fibrinogen or endothelial dysfunction of VWF (50). However, since two individual inflammatory markers and two combinations of markers (two Z-scores) were associated with CRC risk, this argues for a more general role of inflammation. Finally, there were only 166 CRC for the CRP analysis, so there was limited power to examine associations between CRP and CRC risk across different subgroups.

In conclusion, CRP, fibrinogen, and inflammation Z-score were associated with CRC risk in this prospective cohort after adjustment for other CRC risk factors. These biomarkers either reflect inflammation, localized in the colorectum or generalized inflammation, or they may also contribute to stimulating inflammation. This offers further evidence that inflammation plays a role in colorectal carcinogenesis. Inflammation is a potentially modifiable risk factor, so interventions decreasing inflammation (such as aspirin and other NSAIDs) may reduce the CRC risk.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

References

1. Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002; 420:860–7. [PubMed: 12490959]

2. Ohshima H, Tazawa H, Sylla BS, Sawa T. Prevention of human cancer by modulation of chronic inflammatory processes. Mutat Res. 2005; 591:110–22. [PubMed: 16083916]

3. Puntoni M, Marra D, Zanardi S, Decensi A. Inflammation and cancer prevention. Ann Oncol. 2008; 19 (Suppl 7):225–9.

4. Rhodes JM, Campbell BJ. Inflammation and colorectal cancer: IBD-associated and sporadic cancer compared. Trends Mol Med. 2002; 8:10–6. [PubMed: 11796261]

5. Flossmann E, Rothwell PM. British Doctors Aspirin Trial and the UK-TIA Aspirin Trial. Effect of aspirin on long-term risk of colorectal cancer: Consistent evidence from randomised and observational studies. Lancet. 2007; 369:1603–13. [PubMed: 17499602]

6. Erlinger TP, Platz EA, Rifai N, Helzlsouer KJ. C-reactive protein and the risk of incident colorectal cancer. JAMA. 2004; 291:585–90. [PubMed: 14762037]

7. Gunter MJ, Stolzenberg-Solomon R, Cross AJ, et al. A prospective study of serum C-reactive protein and colorectal cancer risk in men. Cancer Res. 2006; 66:2483–7. [PubMed: 16489056]

8. Il'yasova D, Colbert LH, Harris TB, et al. Circulating levels of inflammatory markers and cancer risk in the Health Aging and Body Composition cohort. Cancer Epidemiol Biomarkers Prev. 2005; 14:2413–8. [PubMed: 16214925]

9. Otani T, Iwasaki M, Sasazuki S, Inoue M, Tsugane S. Japan Public Health Center-Based Prospective Study Group. Plasma C-reactive protein and risk of colorectal cancer in a nested case-control study: Japan public health center-based prospective study. Cancer Epidemiol Biomarkers Prev. 2006; 15:690–5. [PubMed: 16614110]

10. Lee YJ, Lee HR, Nam CM, Hwang UK, Jee SH. White blood cell count and the risk of colon cancer. Yonsei Med J. 2006; 47:646–56. [PubMed: 17066508]

11. Margolis KL, Rodabough RJ, Thomson CA, Lopez AM, McTiernan A. Women's Health Initiative Research Group. Prospective study of leukocyte count as a predictor of incident breast, colorectal, endometrial, and lung cancer and mortality in postmenopausal women. Arch Intern Med. 2007; 167:1837–44. [PubMed: 17893304]

12. Ko WF, Helzlsouer KJ, Comstock GW. Serum albumin, bilirubin, and uric acid and the anatomic site-specific incidence of colon cancer. J Natl Cancer Inst. 1994; 86:1874–5. [PubMed: 7990163]

13. Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med. 1999; 340:448–54. [PubMed: 9971870]

14. Macarthur M, Hold GL, El-Omar EM. Inflammation and cancer II. Role of chronic inflammation and cytokine gene polymorphisms in the pathogenesis of gastrointestinal malignancy. Am J Physiol Gastrointest Liver Physiol. 2004; 286:515–20.

15. Clevers H. At the crossroads of inflammation and cancer. Cell. 2004; 118:671–4. [PubMed: 15369667]

16. The ARIC investigators. The Atherosclerosis Risk in Communities (ARIC) study: Design and objectives. Am J Epidemiol. 1989; 129:687–702. [PubMed: 2646917]

17. Ferrario M, Carpenter MA, Chambless LE. Reliability of body fat distribution measurements. the ARIC study baseline cohort results. Atherosclerosis Risk in Communities study. Int J Obes Relat Metab Disord. 1995; 19:449–57. [PubMed: 8520633]

18. Atherosclerosis Risk in Communities (ARIC) study. ARIC documentation. January 16. 2010 Available from: http://www.cscc.unc.edu/ARIC

19. Willett WC, Sampson L, Stampfer MJ, et al. Reproducibility and validity of a semiquantitative food frequency questionnaire. Am J Epidemiol. 1985; 122:51–65. [PubMed: 4014201]

20. Baecke JA, Burema J, Frijters JE. A short questionnaire for the measurement of habitual physical activity in epidemiological studies. Am J Clin Nutr. 1982; 36:936–42. [PubMed: 7137077]

21. Papp AC, Hatzakis H, Bracey A, Wu KK. ARIC hemostasis study--I. Development of a blood collection and processing system suitable for multicenter hemostatic studies. Thromb Haemost. 1989; 61:15–9. [PubMed: 2526384]

22. Folsom AR, Wu KK, Rosamond WD, Sharrett AR, Chambless LE. Prospective study of hemostatic factors and incidence of coronary heart disease: the Atherosclerosis Risk in Communities (ARIC). Circulation. 1997; 96:1102–8. [PubMed: 9286936]

23. Duncan BB, Schmidt MI, Offenbacher S, Wu KK, Savage PJ, Heiss G. Factor VIII and other hemostasis variables are related to incident diabetes in adults. The Atherosclerosis Risk in Communities (ARIC) study. Diabetes Care. 1999; 22:767–72. [PubMed: 10332679]

24. Folsom AR, Lutsey PL, Astor BC, Cushman M. C-reactive protein and venous thromboembolism. A prospective investigation in the ARIC cohort. Thromb Haemost. 2009; 102:615–9. [PubMed: 19806245]

25. Ahmed RL, Schmitz KH, Anderson KE, Rosamond WD, Folsom AR. The metabolic syndrome and risk of incident colorectal cancer. Cancer. 2006; 107:28–36. [PubMed: 16721800]

26. Minnesota Department of Health (MDH). June 20. 2010 Available from: http://www.health.state.mn.us/

27. Pearson TA, Mensah GA, Alexander RW, et al. Markers of inflammation and cardiovascular disease: Application to clinical and public health practice: A statement for healthcare professionals from the centers for disease control and prevention and the American Heart Association. Circulation. 2003; 107:499–511. [PubMed: 12551878]

28. Danesh J, Lewington S, et al. Fibrinogen Studies Collaboration. Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: An individual participant meta-analysis. JAMA. 2005; 294:1799–809. [PubMed: 16219884]

29. Zhang SM, Buring JE, Lee IM, Cook NR, Ridker PM. C-reactive protein levels are not associated with increased risk for colorectal cancer in women. Ann Intern Med. 2005; 142:425–32. [PubMed: 15767620]

30. Allin KH, Bojesen SE, Nordestgaard BG. Baseline C-reactive protein is associated with incident cancer and survival in patients with cancer. J Clin Oncol. 2009; 27:2217–24. [PubMed: 19289618]

31. McMillan DC, Crozier JE, Canna K, Angerson WJ, McArdle CS. Evaluation of an inflammation-based prognostic score (GPS) in patients undergoing resection for colon and rectal cancer. Int J Colorectal Dis. 2007; 22:881–6. [PubMed: 17245566]

32. Ishizuka M, Nagata H, Takagi K, Horie T, Kubota K. Inflammation-based prognostic score is a novel predictor of postoperative outcome in patients with colorectal cancer. Ann Surg. 2007; 246:1047–51. [PubMed: 18043109]

33. Siemes C, Visser LE, Coebergh JW, et al. C-reactive protein levels, variation in the C-reactive protein gene, and cancer risk: The Rotterdam Study. J Clin Oncol. 2006; 24:5216–22. [PubMed: 17114654]

34. Ito Y, Suzuki K, Tamakoshi K, et al. Colorectal cancer and serum C-reactive protein levels: A case-control study nested in the JACC study. J Epidemiol. 2005; 15 (Suppl 2):185–9.

35. Trichopoulos D, Psaltopoulou T, Orfanos P, Trichopoulou A, Boffetta P. Plasma C-reactive protein and risk of cancer: A prospective study from Greece. Cancer Epidemiol Biomarkers Prev. 2006; 15:381–4. [PubMed: 16492932]

36. Heikkila K, Harris R, Lowe G, et al. Associations of circulating C-reactive protein and interleukin-6 with cancer risk: Findings from two prospective cohorts and a meta-analysis. Cancer Causes Control. 2009; 20:15–26. [PubMed: 18704713]

37. Tsilidis KK, Branchini C, Guallar E, Helzlsouer KJ, Erlinger TP, Platz EA. C-reactive protein and colorectal cancer risk: A systematic review of prospective studies. Int J Cancer. 2008; 123:1133–40. [PubMed: 18528865]

38. Knekt P, Hakulinen T, Leino A, Heliovaara M, Reunanen A, Stevens R. Serum albumin and colorectal cancer risk. Eur J Clin Nutr. 2000; 54:460–2. [PubMed: 10878646]

39. Okada F, Kawaguchi T, Habelhah H, et al. Conversion of human colonic adenoma cells to adenocarcinoma cells through inflammation in nude mice. Lab Invest. 2000; 80:1617–28. [PubMed: 11092522]

40. Gunter MJ, Canzian F, Landi S, Chanock SJ, Sinha R, Rothman N. Inflammation-related gene polymorphisms and colorectal adenoma. Cancer Epidemiol Biomarkers Prev. 2006; 15:1126–31. [PubMed: 16775170]

41. Tsilidis KK, Helzlsouer KJ, Smith MW, et al. Association of common polymorphisms in IL10, and in other genes related to inflammatory response and obesity with colorectal cancer. Cancer Causes Control. 2009; 20:1739–51. [PubMed: 19760027]

42. Theodoropoulos G, Papaconstantinou I, Felekouras E, et al. Relation between common polymorphisms in genes related to inflammatory response and colorectal cancer. World J Gastroenterol. 2006; 12:5037–43. [PubMed: 16937502]

43. Steinbrecher KA, Horowitz NA, Blevins EA, et al. Colitis-associated cancer is dependent on the interplay between the hemostatic and inflammatory systems and supported by integrin {alpha}M{beta}2 engagement of fibrinogen. Cancer Res. 2010; 70:2634–43. [PubMed: 20233870]

44. Weitberg AB, Weitzman SA, Destrempes M, Latt SA, Stossel TP. Stimulated human phagocytes produce cytogenetic changes in cultured mammalian cells. N Engl J Med. 1983; 308:26–30. [PubMed: 6292719]

45. Pasceri V, Willerson JT, Yeh ET. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation. 2000; 102:2165–8. [PubMed: 11056086]

46. Kawanami D, Maemura K, Takeda N, et al. C-reactive protein induces VCAM-1 gene expression through NF-kappaB activation in vascular endothelial cells. Atherosclerosis. 2006; 185:39–46. [PubMed: 16002075]

47. John BJ, Abulafi AM, Poullis A, Mendall MA. Chronic subclinical bowel inflammation may explain increased risk of colorectal cancer in obese people. Gut. 2007; 56:1034–5. [PubMed: 17566047]

48. Myers GL, Rifai N, Tracy RP, et al. CDC/AHA workshop on markers of inflammation and cardiovascular disease: Application to clinical and public health practice: Report from the laboratory science discussion group. Circulation. 2004; 110:545–9.

49. Koenig W, Sund M, Frohlich M, Lowel H, Hutchinson WL, Pepys MB. Refinement of the association of serum C-reactive protein concentration and coronary heart disease risk by correction for within-subject variation over time: The MONICA Augsburg studies, 1984 and 1987. Am J Epidemiol. 2003; 158:357–64. [PubMed: 12915501]

50. Wojtukiewicz MZ, Sierko E, Rak J. Contribution of the hemostatic system to angiogenesis in cancer. Semin Thromb Hemost. 2004; 30:5–20. [PubMed: 15034794]

Table 1

Incidence rates of colorectal cancer (CRC) (1987–2006) adjusted for age, gender, race, and center in relation to selected characteristics at Visit 1, ARIC study

	Number of participants (N =13,414)		
Characteristic at Visit 1 (1987–89)	CRC cases(N=308)	Person-years(PY)	Incidence rate per 1000 PYs, (95% CI)
Age *			
45–49	47	66,489	0.69 (0.52; 0.92)
50–54	85	62,102	1.34 (1.08; 1.66)
55–59	89	54,886	1.60 (1.29; 1.97)
60–64	87	47,033	1.83 (1.48; 2.26)
Gender **			
Male	160	128,428	1.48 (1.26; 1.74)
Female	148	102,080	1.09 (0.92; 1.29)
Race ***			
African American	92	58,611	1.58 (1.29; 1.94)
Caucasian	216	171,897	1.17 (1.01; 1.34)
BMI, kg/m^2			
≤24.99	84	75,943	1.11 (0.89; 1.37)
25–29.99	119	91,949	1.17 (0.97; 1.41)
≥30	105	62,337	1.57 (1.29; 1.92)
Diabetes			
No	262	23,549	1.21 (1.15; 1.28)
Yes	46	20,905	1.64 (1.44; 1.88)
Aspirin			
No	173	122,899	1.29 (1.20; 1.39)
Yes	131	105,668	1.21 (1.12; 1.31)
Education			
< High school	85	50,801	1.36 (1.07; 1.72)
High school	97	75,423	1.30 (1.06; 1.59)
> High school	126	103,944	1.18 (0.99; 1.41)
Smoking			
Never	133	99,817	1.18 (0.99; 1.41)
Former	98	75,136	1.30 (1.06; 1.59)
Current	77	55,422	1.36 (1.07; 1.72)
Alcohol			
Never	77	58,336	1.18 (0.92; 1.52)
Former	56	41,320	1.18 (0.90; 1.55)

	Number of participants (N =13,414)		
Characteristic at Visit 1 (1987–89)	**CRC cases(N=308)**	**Person-years(PY)**	**Incidence rate per 1000 PYs, (95% CI)**
Current	173	129,861	1.31 (0.11; 1.53)
HRT (in women)			
Never	99	81,948	1.15 (1.06; 1.26)
Ever	48	41,947	1.10 (0.99; 1.23)

[*] Adjusted for race, gender, and center.

[**] Adjusted for age (continuous), race and center.

[***] Adjusted for age (continuous), and gender.

Table 2

Mean value or prevalence of characteristics across inflammation Z-score quartiles in 13,414 participants free of cancer, at Visit 1 (1987–89), ARIC study

ARIC Characteristics Mean or prevalence (%)	Z-score quartiles			
	< −2.12	−2.12–(−)0.32	−0.31—1.72	≥1.73
Age (y)	52.6	53.6	54.5	55.0
Race (% Caucasian)	80.8	78.1	75.2	61.9
Sex (% Female)	48.4	54.1	56.4	61.4
BMI (kg/m^2)	26.1	27.0	28.0	29.8
Sport index	2.6	2.5	2.4	2.3
>High school education, (%)	51.9	47.4	42.7	36.5
Current smoker, (%)	13.9	21.5	29.3	35.2
Current alcohol intake, (%)	64.5	59.2	54.8	47.0
Aspirin, recent use (%)	45.2	46.8	46.3	47.0
Current HRT, (% in women)	22.8	27.3	26.3	23.6
Diabetes (%)	5.0	7.2	10.7	20.5
Fibrinogen (mg/dL)	256	282	308	357
WBC count[*] (×10^9 cells/L)	5.7	5.8	5.8	6.0
VWF (%)	81	102	122	162
FVIII (%)	101	119	135	167
Albumin (g/dL)	4.05	3.92	3.84	3.70

[*] Geometric means are presented for WBC since WBC count was log transformed.

Table 3

Mean value or prevalence of characteristics across quartiles of C-reactive protein (CRP) in 9,836 participants free of cancer at Visit 4 (1996–98), ARIC study

Characteristics	CRP (mg/L) quartiles			
	<1.1	1.1–2.4	2.5–5.6	>5.6
Mean or frequency (%)	N=2,454	N=2,460	N=2,461	N=2,461
Age (y)	62.5	62.8	62.7	62.4
Race (% Caucasian)	82.7	86.0	80.7	75.4
Sex (% Female)	42.5	48.5	60.7	70.0
BMI (kg/m^2)	26.1	28.3	29.7	31.5
Sport index[†]	2.7	2.6	2.5	2.4
>High school education, (%)	53.7	48.8	44.7	41.7
Current smokers, (%)	11.2	13.6	15.2	18.7
Current alcohol intake, (%)	54.1	53.7	48.4	41.4
Aspirin, recent use (%)	52.9	54.7	57.9	61.7
Diabetes (%)	10.4	14.0	19.3	24.6
Current HRT, (% of women)	29.3	34.6	42.5	51.0

[†] Data were collected at Visit 3 (1993–95).

Table 4

Hazard ratios (HR) of colorectal cancer (CRC) in relation to inflammatory markers and inflammation Z-score at Visit 1 in the ARIC study, 1987–2006

Inflammatory marker (quartiles)	Number of CRC	Person-years	HR (95%CI), adjusted for age, race, sex, and center	HR (95%CI), multivariate-adjusted[*]
Fibrinogen (mg/dL)				
≤259	58	60,556	reference	reference
260–294	75	59,613	1.27 (0.90; 1.79)	1.30 (0.91; 1.85)
295–336	90	56,962	1.55 (1.11; 2.16)	1.50 (1.06; 2.13)
≥337	85	53,378	1.55 (1.10; 2.18)	1.50 (1.05; 2.15)
p-trend			0.001	0.03
VWF (%)				
≤83	61	60,013	reference	reference
84–109	85	58,827	1.33 (0.95; 1.84)	1.30 (0.93; 1.84)
110–142	73	57,826	1.11 (0.79; 1.56)	1.07 (0.76; 1.52)
≥143	89	53,842	1.37 (0.98; 1.92)	1.30 (0.93; 1.84)
p-trend			0.17	0.33
FVIII (%)				
≤104	66	58,721	reference	reference
105–126	83	61,355	1.13 (0.82;1.57)	1.13 (0.82; 1.58)
127–150	71	56,076	1.03 (0.73; 1.44)	1.03 (0.73; 1.46)
≥151	88	54,357	1.26 (0.90; 1.75)	1.17 (0.83; 1.65)
p-trend			0.84	0.54
WBC (×10^9 cells/L)				
≤4.8	79	62,251	reference	reference
4.9–5.8	65	59,428	0.89 (0.64; 1.24)	0.86 (0.61; 1.21)
5.9–7.0	86	53,894	1.32 (0.97; 1.79)	1.26 (0.91; 1.74)
≥7.1	78	54,935	1.21 (0.88; 1.66)	1.13 (0.79; 1.60)
p-trend			0.07	0.20
Albumin (g/dL)				
≤3.7	94	68,412	reference	reference
3.8	41	34,395	0.86 (0.60; 1.24)	0.89 (0.61; 1.29)
3.8–3.9	99	68,633	1.05 (0.79; 1.39)	1.09 (0.81; 1.46)
≥3.9	74	59,069	0.92 (0.79; 1.26)	0.94 (0.68; 1.30)
p-trend			0.85	0.94
Z-score				
< −2.12	58	59,810	reference	reference
2.12-(−)0.32	76	58,240	1.30 (0.92; 1.83)	1.30 (0.91; 1.84)
−0.31–1.72	74	57,608	1.23 (0.87; 1.75)	1.19 (0.83; 1.71)
≥1.73	100	54,851	1.73 (1.24; 2.42)	1.65 (1.15; 2.35)

Inflammatory marker (quartiles)	Number of CRC	Person-years	HR (95%CI), adjusted for age, race, sex, and center	HR (95%CI), multivariate-adjusted[*]
p-trend			0. 002	0.01

[*] Adjusted for age, race, center, education, BMI, aspirin use, smoking status and pack-years of smoking, gender-HRT, and diabetes.

Table 5

Multivariate-adjusted hazard ratios (HR) of colon and rectal cancers in relation to fibrinogen and inflammation Z-score, ARIC study, 1987–2006

Inflammatory marker(quartiles)	HR (95%CI), multivariate-adjusted[*]	
	Colon cancer	Rectal cancer
Fibrinogen (mg/dL)		
≤259	reference	reference
260–294	1.24 (0.82; 1.88)	1.55 (0.79; 3.03)
295–336	1.48 (0.98; 2.22)	1.65 (0.84; 3.24)
≥337	1.75 (1.16; 2.63)	0.89 (0.40; 1.95)
p-trend	0.005	0.84
Z-score		
< −2.12	reference	reference
−2.12-(−)0.32	1.41 (0.92; 2.16)	1.14 (0.62; 2.11)
−0.31−1.72	1.49 (0.97; 2.29)	0.70 (0.35; 1.39)
≥1.73	2.18 (1.43; 3.31)	0.76 (0.38; 1.53)
p-trend	0. 0003	0.25

[*] Adjusted for age, race, center, education, BMI, aspirin use, smoking status and pack-years of smoking, diabetes, and gender-HRT at Visit 1.

Table 6

Hazard ratios (HR) of colorectal cancer (CRC) in relation to C-reactive protein (CRP), ARIC study, 1996–2006

CRP quartiles(mg/L)	Number of cancers	Person- years	HR (95%CI), adjusted for age, race, sex, and center	HR (95%CI), multivariate-adjusted[*]
			CRC	
<1.09	28	22,232	reference	reference
1.09–2.44	45	22,078	1.62 (1.01; 2.60)	1.53 (0.90; 2.60)
2.44–5.64	49	21,836	1.83 (1.15; 2.93)	1.84 (1.08; 3.13)
>5.64	29	14,799	1.70 (1.04; 2.76)	1.97 (1.13; 3.43)
p-trend			0.03	0.02
			Colon cancer	
<1.09	22	22,128	reference	reference
1.09–2.44	36	22,001	1.67 (0.98; 2.84)	1.48 (0.83; 2.65)
2.44–5.64	38	21,717	1.85 (1.09; 3.15)	1.78 (0.99; 3.20)
>5.64	37	21,328	1.90 (1.11; 3.26)	2.06 (1.12; 3.78)
p-trend			0.02	0.02
			Rectal cancer	
<1.09	7	22,297	reference	reference
1.09–2.44	10	22,208	1.39(0.53; 3.65)	1.67 (0.54; 5.20)
2.44–5.64	11	21,960	1.52 (0.58; 3.95)	1.78 (0.56; 5.71)
>5.64	7	21,560	0.95 (0.33; 2.77)	1.37 (0.38; 4.92)
			0.98	0.63

[*] Adjusted for age, race, center, education, BMI, aspirin use, smoking status, gender-HRT, and diabetes.